Belimumab: A Review in Systemic Lupus Erythematosus

Area of Science:

• Immunology
• Rheumatology
• Pharmacology

Background:

• Systemic lupus erythematosus (SLE) is a chronic autoimmune disease impacting multiple organs.
• Current treatments for SLE often have limitations, necessitating novel therapeutic approaches.
• Belimumab is a targeted biologic therapy for SLE.

Purpose of the Study:

• To evaluate the efficacy and safety of belimumab as an add-on therapy in adult patients with active, autoantibody-positive SLE.
• To assess belimumab's impact on disease activity, flares, and patient-reported outcomes.
• To examine the long-term effectiveness and tolerability of belimumab treatment.

Main Methods:

• Phase III clinical trials involving intravenous (IV) or subcutaneous (SC) belimumab plus standard therapy.
• Assessment of overall disease activity, flare incidence and severity, and organ system involvement.
• Evaluation of steroid-sparing effects, quality of life, and fatigue.

Main Results:

• Belimumab significantly reduced overall SLE disease activity and the incidence/severity of flares.
• Sustained disease control was observed with long-term IV belimumab treatment (up to 10 years).
• Clinically meaningful improvements in quality of life and fatigue were noted, alongside steroid-sparing effects.

Conclusions:

• Belimumab is an effective and well-tolerated treatment option for active, autoantibody-positive SLE patients inadequately controlled by standard therapy.
• The availability of both IV and self-administered SC formulations enhances treatment flexibility.
• Belimumab offers a valuable therapeutic strategy for managing SLE, improving patient outcomes and quality of life.